Screening for Neurotoxicity with Microelectrode Array

Area of Science:

• Neuroscience
• Toxicology
• Drug Discovery

Background:

• Current in vitro cytotoxicity assays struggle to predict neurotoxicity and seizurogenic liabilities.
• Limitations in predicting neural network disruptions lead to late-stage detection of adverse effects in vivo.
• Significant time and financial resources are often invested before identifying these detrimental effects.

Purpose of the Study:

• To develop a reliable, high-throughput in vitro method for assessing neurotoxic and seizure-inducing compound effects.
• To enable early identification of liabilities during the drug discovery process.
• To reduce late-stage failures in drug development.

Main Methods:

• Utilized a 48-well microelectrode array (MEA) platform for in vitro screening.
• Employed custom data analysis algorithms alongside commercial tools.
• Analyzed spike file data from cryogenically preserved rat cortical neurons.

Main Results:

• Successfully developed an in vitro screening tool capable of identifying neurotoxic and seizurogenic chemical entities.
• Demonstrated the utility of MEA technology for detecting adverse neural effects.
• Provided a method for early-stage assessment of compound safety.

Conclusions:

• The developed MEA-based platform offers a promising solution for early detection of neurotoxicity and seizurogenic liabilities.
• This high-throughput screening tool can significantly improve the efficiency of drug discovery.
• Implementing this method can help mitigate risks associated with late-stage identification of adverse neural effects.